AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 316459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 30
Study 316459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 316459 — intervention group
Group type: COMPARATOR
Intervention: Propoxyphene
Number of subjects: 30
Study 31136431 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticoagulants
Number of subjects: 32663
Study 31136431 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 32663
Study 28919061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 833
Study 28919061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 833
Study 28919061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study 24925985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 141
Study 24925985 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication (paroxetine)
Number of subjects: 141
Study 23344769 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rt-PA (group A)
Number of subjects: 103
Study 23344769 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rt-PA (group B)
Number of subjects: 103
Study 23344769 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 5 mg rt-PA (both groups)
Number of subjects: 103
Study 21300299 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR) program for 6 months
Number of subjects: 75
Study 21300299 — intervention group
Group type: COMPARATOR
Intervention: Generic instructions for maintaining physical activity and a correct lifestyle (Control)
Number of subjects: 75
Study 19996045 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices (motivational interviewing intervention)
Number of subjects: 186
Study 19996045 — intervention group
Group type: COMPARATOR
Intervention: Specialty care alone (control)
Number of subjects: 186
Study 16759048 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance by genotypic resistance results
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy with less daily doses
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: More pronounced 3-month viral load drop
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival without new AIDS events/death
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous AIDS events
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline viral load
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Less pronounced 3-month viral load drop
Number of subjects: 174
Study 16759048 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline protease substitutions K20M/R and 184V
Number of subjects: 174
Study 14716794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage (group 1; n = 58)
Number of subjects: 116
Study 14716794 — intervention group
Group type: EXPERIMENTAL
Intervention: No drain with fibrin sealant (group 2; n = 29)
Number of subjects: 116
Study 14716794 — intervention group
Group type: COMPARATOR
Intervention: No drain with no intervention (group 3; n = 29)
Number of subjects: 116
Study 14716794 — intervention group
Group type: COMPARATOR
Intervention: No drain (both group 2 and group 3)
Number of subjects: 116
Study 11732951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide, 250 microg
Number of subjects: 80
Study 11732951 — intervention group
Group type: COMPARATOR
Intervention: Nebulized isotonic sodium chloride solution, 1 mL (Control)
Number of subjects: 80
Study 9209775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 12.5 mg
Number of subjects: 36
Study 9209775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 25 mg
Number of subjects: 36
Study 9209775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 50 mg
Number of subjects: 36
Study 9209775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 100 mg
Number of subjects: 36
Study 9209775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan suppository 50 mg (twice a day for 11 doses)
Number of subjects: 36
Study 9209775 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository (twice a day for 11 doses)
Number of subjects: 36
Study 8480688 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg Zn (as gluconate)/d for 60 days
Number of subjects: 18
Study 8480688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3304688 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP plus 2 years of oral maintenance chemotherapy
Number of subjects: 54
Study 3304688 — intervention group
Group type: EXPERIMENTAL
Intervention: CMOPP
Number of subjects: 54
Study 29206056 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use autoinjector
Number of subjects: 97
Study 29206056 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable autoinjector
Number of subjects: 97
Study 26727163 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy
Number of subjects: 222
Study 26727163 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 222
Study 26727163 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (TrPAL ≤ ULN)
Number of subjects: 222
Study 26727163 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 plus chemotherapy (TrPAL > ULN)
Number of subjects: 222
Study 24598493 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC posts placed (Subgroup 1.1)
Number of subjects: 120
Study 24598493 — intervention group
Group type: EXPERIMENTAL
Intervention: No posts (Subgroup 1.2)
Number of subjects: 120
Study 24598493 — intervention group
Group type: COMPARATOR
Intervention: No root canal preparation (Subgroup 1.3)
Number of subjects: 120
Study 24598493 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC posts placed (Subgroup 2.1)
Number of subjects: 120
Study 24598493 — intervention group
Group type: EXPERIMENTAL
Intervention: No posts (Subgroup 2.2)
Number of subjects: 120
Study 24598493 — intervention group
Group type: COMPARATOR
Intervention: No root canal preparation (Subgroup 2.3)
Number of subjects: 120
Study 23141853 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention plus optimal medical therapy (PCI)
Number of subjects: 2201
Study 23141853 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (MED) alone
Number of subjects: 2201
Study 23141853 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated HF hospitalization
Number of subjects: 2201
Study 23141853 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HF
Number of subjects: 2201
Study 20371820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 100
Study 20371820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 18977955 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 coadministered at 2 and 4 months
Number of subjects: 484
Study 18977955 — intervention group
Group type: COMPARATOR
Intervention: RIX4414 administered separately at 3 and 5 months
Number of subjects: 484
Study 15719745 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) alone (Group A)
Number of subjects: 84
Study 15719745 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) plus Compound Salvia injection (CSI) (Group B)
Number of subjects: 84
Study 15719745 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISD, 15 mg, 4 times per day) plus vitamin C (Group C)
Number of subjects: 84
Study 15719745 — intervention group
Group type: COMPARATOR
Intervention: Group A (ISD alone)
Number of subjects: 84
Study 15719745 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (ISD + CSI)
Number of subjects: 84
Study 15719745 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (ISD + vitamin C)
Number of subjects: 84
Study 12842299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome group
Number of subjects: 8
Study 12842299 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age and ethnicity with no history of prenatal alcohol exposure)
Number of subjects: 8
Study 12842299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during cued-navigation trials
Number of subjects: 8
Study 11021737 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) with ranitidine (150 mg twice daily for 4 days before day 1 of one of the first two courses and 150 mg given 2 h before the first topotecan dose)
Number of subjects: 13
Study 11021737 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) without ranitidine
Number of subjects: 13
Study 8781290 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein deprivation
Number of subjects: 10
Study 8781290 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 10
Study 8781290 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with hypoalbuminemia and inflammatory syndrome
Number of subjects: 10
Study 1478401 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis (4 L/day)
Number of subjects: 53
Study 1478401 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (225 to 300 mg/day) + Furosemide (40 to 80 mg/day)
Number of subjects: 53
Study 6471773 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-Interferon (Fiblaferon) treatment (10(5) U/kg daily for 3 weeks followed by 3 times a week for 21 weeks)
Number of subjects: 72
Study 6471773 — intervention group
Group type: COMPARATOR
Intervention: No beta-Interferon treatment
Number of subjects: 72
Study 6471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (adriamycine, cyclophosphamide, vincristine, dacarbazine)
Number of subjects: 72
Study 6471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 72
Study 6471773 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-Interferon
Number of subjects: 72
Study 6471773 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 72
Study 31264493 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL therapy
Number of subjects: 12
Study 31264493 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group without ALL
Number of subjects: 12
Study 30051507 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 26863155 — intervention group
Group type: EXPERIMENTAL
Intervention: trans‐resveratrol‐based supplement (Longevinex®)
Number of subjects: 34
Study 26863155 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 24684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (monthly) and sirolimus (daily) after alemtuzumab induction
Number of subjects: 20
Study 24684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (monthly)
Number of subjects: 20
Study 24684552 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept-based regimens supplemented by oral immunosuppression
Number of subjects: 20
Study 24684552 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20
Study 22933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepax® (test formulation)
Number of subjects: 24
Study 22933049 — intervention group
Group type: COMPARATOR
Intervention: Lamictal® (reference formulation)
Number of subjects: 24
Study 18930212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation
Number of subjects: 191
Study 18930212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel electrocoagulation
Number of subjects: 191
Study 18930212 — intervention group
Group type: COMPARATOR
Intervention: Suture (control group)
Number of subjects: 191
Study 17601464 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency whole-body vibration (WBV) at 20Hz for 3 minutes a day, 3 days a week for 3 months
Number of subjects: 69
Study 15358571 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (CS) applied for 48 hours before prick-testing.
Number of subjects: 13
Study 15358571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of methylprednisolone immediately after prick-testing.
Number of subjects: 13
Study 15358571 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated area for topical CS application).
Number of subjects: 13
Study 11401000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 20 mg
Number of subjects: 79
Study 11401000 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone IM 2 mg
Number of subjects: 79
Study 9543153 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 2.37 +/- 2.27 microg)
Number of subjects: 87
Study 9543153 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 3.03 +/- 2.39 microg)
Number of subjects: 87
Study 9543153 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (CD25 = 1.01 +/- 1.17 microg)
Number of subjects: 87
Study 9543153 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (CD25 = 3.44 +/- 2.24 microg)
Number of subjects: 87
Study 8046805 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-triggered therapy (chlordiazepoxide administered only in response to withdrawal symptoms)
Number of subjects: 101
Study 8046805 — intervention group
Group type: COMPARATOR
Intervention: Fixed-schedule therapy (standard course of chlordiazepoxide four times daily with additional medication as needed)
Number of subjects: 101
Study 3054280 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before test meals
Number of subjects: 13
Study 3054280 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 13
Study 3054280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of acarbose treatment
Number of subjects: 13
Study 30086709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 μg/kg DEX
Number of subjects: 100
Study 30086709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/kg DEX
Number of subjects: 100
Study 30086709 — intervention group
Group type: COMPARATOR
Intervention: 0.25 μg/kg DEX
Number of subjects: 100
Study 30086709 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg DEX
Number of subjects: 100
Study 30086709 — intervention group
Group type: EXPERIMENTAL
Intervention: All DEX groups
Number of subjects: 100
Study 30086709 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 27485252 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery cognitive bias modification (imagery CBM)
Number of subjects: 101
Study 25399973 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 51
Study 25399973 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/Carboplatin (Carboplatin: AUC 5 mg × ml⁻¹ × min⁻¹, 21-day cycle; Paclitaxel: 200 mg/m², 21-day cycle)
Number of subjects: 51
Study 24349389 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB)
Number of subjects: 60
Study 24349389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure chlorogenic acids (CGA)
Number of subjects: 60
Study 20384598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 9858
Study 20384598 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 9858
Study 18695086 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) levels
Number of subjects: 2412
Study 15923969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 154
Study 15923969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 12629105 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg cocaine
Number of subjects: 30
Study 12629105 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 10576189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 microg every 4 hours as needed
Number of subjects: 108
Study 10576189 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 108
Study 10576189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 108
Study 10576189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol and Intravenous oxytocin
Number of subjects: 108
Study 8740599 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental back muscle pain induced by bolus injection of 5% hypertonic saline
Number of subjects: 10
Study 8740599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain (CLBP)
Number of subjects: 10
Study 8740599 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex- and age-matched)
Number of subjects: 10
Study 1662638 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, 250 mg on days 2-5)
Number of subjects: 366
Study 1662638 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (500 mg b.i.d. for ten days)
Number of subjects: 366
Study 7046908 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg/m2 orally three times a week) with chemotherapy
Number of subjects: 381
Study 7046908 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dosage of levamisole (2.5 mg/kg or 100 mg/m2 three times a week, every other week) with chemotherapy
Number of subjects: 381
Study 7046908 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (chemotherapy without levamisole)
Number of subjects: 381
Study 30799154 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management goals in nursing visits (pain management, fall prevention)
Number of subjects: 367
Study 28657417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg per day)
Number of subjects: 1776
Study 28657417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1776
Study 25646169 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing fluoride, triclosan, cetylpyridinium chloride, and essential oils
Number of subjects: 40
Study 25646169 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated toothpaste (control)
Number of subjects: 40
Study 25646169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 23543398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3014
Study 23543398 — intervention group
Group type: COMPARATOR
Intervention: No Clopidogrel
Number of subjects: 3014
Study 21845387 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of dexamethasone (8 mg)
Number of subjects: 67
Study 21845387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of dexamethasone (8 mg)
Number of subjects: 67
Study 21845387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 67
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm PTFE graft
Number of subjects: 102
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm PTFE graft
Number of subjects: 102
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with underlying diseases (hypertension and diabetes)
Number of subjects: 102
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without underlying diseases
Number of subjects: 102
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rates in patients with underlying diseases
Number of subjects: 102
Study 20535250 — intervention group
Group type: EXPERIMENTAL
Intervention: Complication rates in patients without underlying diseases
Number of subjects: 102
Study 20535250 — intervention group
Group type: COMPARATOR
Intervention: Comparison of graft sizes
Number of subjects: 102
Study 16167288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID (n = 188)
Number of subjects: 371
Study 16167288 — intervention group
Group type: COMPARATOR
Intervention: Concomitant brimonidine tartrate 0.2% BID and timolol 0.5% BID (n = 183)
Number of subjects: 371
Study 16167288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (fixed-combination and concomitant)
Number of subjects: 371
Study 16167288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 371
Study 14634377 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy with ventricular arrhythmias
Number of subjects: 51
Study 14634377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arrhythmias)
Number of subjects: 51
Study 10656431 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 67
Study 10656431 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 67
Study 8679790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH intravenously 20 min before ECT
Number of subjects: 14
Study 8679790 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously 20 min before ECT
Number of subjects: 14
Study 8679790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH just prior to ECT
Number of subjects: 14
Study 8679790 — intervention group
Group type: COMPARATOR
Intervention: ECT alone
Number of subjects: 14
Study 2066545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 0
Study 2066545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2066545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime and Placebo
Number of subjects: 0
Study 6606576 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (aorto-coronary bypass surgery)
Number of subjects: 76
Study 6606576 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 76
Study 31298720 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF only group
Number of subjects: 80